Comparable outcomes with a potential functional advantage of PCL preservation in medial-stabilized total knee arthroplasty: A systematic review and meta-analysis from the FP-UCBM Knee Study Group

内侧稳定型全膝关节置换术中保留后交叉韧带可能具有功能优势,且疗效相当:FP-UCBM膝关节研究组的系统评价和荟萃分析

阅读:1

Abstract

PURPOSE: The management of the posterior cruciate ligament (PCL) in medial-stabilized (MS) total knee arthroplasty (TKA) remains a topic of debate. This systematic review and meta-analysis investigate whether preserving or substituting the PCL in mechanical alignment (MA) MS-TKA impacts clinical, functional and radiographic outcomes. METHODS: Systematic literature searches (PubMed-Medline, Scopus and Web of Science) followed PRISMA guidelines. Studies comparing PCL-retaining (PCL-r) and PCL-substituting (PCL-s) approaches in primary MS-TKA with MA were included. Outcomes analyzed included range of motion (ROM), implant survivorship, patient-reported outcome measures (PROMs), complication rates and radiological outcomes. Meta-analyses were performed using Review Manager (RevMan) software 5.4. RESULTS: Overall, seven studies involving 1376 knees met the inclusion criteria. No significant differences were observed between PCL-r and PCL-s cohorts regarding ROM, radiographic outcome or PROMs such as the Forgotten Joint Score, Oxford Knee Score and Knee Society Score (KSS-Knee). A statistically significant difference was observed in KSS-Function favouring the PCL-r group (mean difference = -2.47, p = 0.008). Rates of complications and implant survivorship were comparable between the two techniques. CONCLUSION: Both PCL-r and PCL-s strategies yield largely comparable outcomes in MS-TKA performed with MA. However, a significant difference in KSS-Function favours the PCL-r strategy, suggesting a potential advantage in functional recovery. The choice to retain or resect the PCL should be individualized based on patient characteristics, surgeon preference and implant design, but future studies are needed to explore the clinical implications of this functional benefit. LEVEL OF EVIDENCE: Level III.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。